Default company panoramic image
Logo

Probiodrug AG

New treatment for Alzheimer's, prevention of toxic pE-Abeta, QC-Inhibitor to enter Phase II, disease-modifying, dominant IP, no therapy yet

  • Stage Product In Development
  • Industry Biotechnology
  • Location Halle, SA, Deutschland
  • Currency USD
  • Founded July 1997
  • Employees 20
  • Website probiodrug.de

Company Summary

Probiodrug discovers and develops novel drugs for neuronal diseases. Its patent portfolio provides a dominant position for glutaminyl cyclase (QC) inhibition with the lead PQ912 ready to enter Phase II. QC, a novel target, is essential for the formation of pyroglutamated (pE) Abeta, which plays a crucial role in the pathogenesis of Alzheimer’s disease (AD). Likewise, the company is pursuing a pE-specific antibody as immunotherapy for AD.

Advisors

  • Default avatar
    SNP Munich
    Lawyer
    Unconfirmed
    Default avatar
    KPMG
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    BB Biotech, IBG, Ed. de Rothschild Investment Partners, IBG,
    Unconfirmed
    Default avatar
    TVM Capital, HBM BioVentures, Life Sciences Partners
    Unconfirmed
    Default avatar
    CFH Group - LBBW Group, Biogen Idec, Wellington Management
    Unconfirmed